Effect of Jianpi Shengxue Tablet on Iron Metabolism and Nutritional Status in Patients with Renal Anemia: A Prospective, Randomized, Open, Parallel Controlled and Multicenter Clinical Study.

OBJECTIVE: This study aimed to analyze the clinical efficacy of the Jianpi Shengxue tablet for treating renal anemia. METHODS: A total of 200 patients with renal anemia from December 2020 to December 2022 were enrolled and randomly divided into two groups. Patients in the control group were treated with polysaccharide-iron complex, and those in the experimental group were administered Jianpi Shengxue tablet. After 8 weeks of continuous treatment, the therapeutic outcomes regarding anemia were compared between the two groups. RESULTS: After treatment, the red blood cell (RBC) count, hematocrit (HCT), reticulocyte percentage (RET), ferritin (SF), serum iron (SI), transferrin saturation (TSAT), and serum albumin (ALB) all increased (P<0.01), and the clinical symptom score and total iron binding capacity decreased (P<0.01) in the experimental group. Moreover, the improvements in RBC, HCT, RET, SF, SI, TAST, ALB, and clinical symptoms (fatigue, anorexia, dull skin complexion, numbness of hands and feet) in the experimental group were significantly greater than those in the control group (P<0.05). The total effective rate for treating renal anemia was significantly higher in the experimental group than in the control group (P<0.01). CONCLUSION: The Jianpi Shengxue tablet demonstrates efficacy in treating renal anemia, leading to significant improvements in the laboratory examination results and clinical symptoms of patients with renal anemia.

[Detection of differentially expressed proteins in the semen of oligospermia patients by SELDI-TOF-MS technology].

OBJECTIVE: To analyze the spectrometric semen protein profiling of oligospermia patients and healthy controls by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS), and to establish a semen marker pattern for the diagnosis of oligospermia. METHODS: Semen samples of 33 oligospermia patients and 31 healthy controls were collected on the CM01O proteinchip. The spectrometric protein profiling was detected by SELDI-TOF-MS and the data analyzed by Biomarker Pattern Software provided by Ciphergen Corp. A primary diagnostic model of oligospermia was established and evaluated by blind test with the 33 patients and 31 healthy controls. RESULTS: A total of 185 protein peaks were detected at the molecular range of 2000-20,000, among which 23 showed significant differences between oligospermia patients and healthy controls (P < 0.05). The diagnostic model consisted of 3 protein peaks, with a sensitivity of 90.9% (30/33) and a specificity of 93.6% (29/31). And the double-blind test generated a sensitivity of 87.8% (29/33) and a specificity of 90.3% (28/31). CONCLUSION: The diagnostic model was successfully established by SELDI-TOF-MS, which could be applied to the differentiation of the spectrometric protein profiling patterns of oligospermia patients and healthy controls.